We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.

Show simple item record

dc.contributor.authorBabcock, Gregory J.
dc.contributor.authorEsshaki, Diana J.
dc.contributor.authorThomas, William D.
dc.contributor.authorAmbrosino, Donna M.
dc.date2022-08-11T08:09:34.000
dc.date.accessioned2022-08-23T16:35:55Z
dc.date.available2022-08-23T16:35:55Z
dc.date.issued2004-04-14
dc.date.submitted2009-03-26
dc.identifier.citationJ Virol. 2004 May;78(9):4552-60.
dc.identifier.issn0022-538X (Print)
dc.identifier.pmid15078936
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38670
dc.description.abstractA novel coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV), has recently been identified as the causative agent of severe acute respiratory syndrome (SARS). SARS-CoV appears similar to other coronaviruses in both virion structure and genome organization. It is known for other coronaviruses that the spike (S) glycoprotein is required for both viral attachment to permissive cells and for fusion of the viral envelope with the host cell membrane. Here we describe the construction and expression of a soluble codon-optimized SARS-CoV S glycoprotein comprising the first 1,190 amino acids of the native S glycoprotein (S(1190)). The codon-optimized and native S glycoproteins exhibit similar molecular weight as determined by Western blot analysis, indicating that synthetic S glycoprotein is modified correctly in a mammalian expression system. S(1190) binds to the surface of Vero E6 cells, a cell permissive to infection, as demonstrated by fluorescence-activated cell sorter analysis, suggesting that S(1190) maintains the biologic activity present in native S glycoprotein. This interaction is blocked with serum obtained from recovering SARS patients, indicating that the binding is specific. In an effort to map the ligand-binding domain of the SARS-CoV S glycoprotein, carboxy- and amino-terminal truncations of the S(1190) glycoprotein were constructed. Amino acids 270 to 510 were the minimal receptor-binding region of the SARS-CoV S glycoprotein as determined by flow cytometry. We speculate that amino acids 1 to 510 of the SARS-CoV S glycoprotein represent a unique domain containing the receptor-binding site (amino acids 270 to 510), analogous to the S1 subunit of other coronavirus S glycoproteins.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=15078936&dopt=Abstract">Link to Article in PubMed</a>
dc.subjectAmino Acids
dc.subjectAnimals
dc.subjectCell Line
dc.subjectCercopithecus aethiops
dc.subjectCodon
dc.subjectFlow Cytometry
dc.subjectHumans
dc.subjectLigands
dc.subjectMembrane Glycoproteins
dc.subjectMutation
dc.subjectReceptors, Virus
dc.subjectSARS Virus
dc.subjectStructure-Activity Relationship
dc.subjectVero Cells
dc.subjectViral Envelope Proteins
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleAmino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor
dc.typeJournal Article
dc.source.journaltitleJournal of virology
dc.source.volume78
dc.source.issue9
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=2526&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1527
dc.identifier.contextkey798502
refterms.dateFOA2022-08-23T16:35:55Z
html.description.abstract<p>A novel coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV), has recently been identified as the causative agent of severe acute respiratory syndrome (SARS). SARS-CoV appears similar to other coronaviruses in both virion structure and genome organization. It is known for other coronaviruses that the spike (S) glycoprotein is required for both viral attachment to permissive cells and for fusion of the viral envelope with the host cell membrane. Here we describe the construction and expression of a soluble codon-optimized SARS-CoV S glycoprotein comprising the first 1,190 amino acids of the native S glycoprotein (S(1190)). The codon-optimized and native S glycoproteins exhibit similar molecular weight as determined by Western blot analysis, indicating that synthetic S glycoprotein is modified correctly in a mammalian expression system. S(1190) binds to the surface of Vero E6 cells, a cell permissive to infection, as demonstrated by fluorescence-activated cell sorter analysis, suggesting that S(1190) maintains the biologic activity present in native S glycoprotein. This interaction is blocked with serum obtained from recovering SARS patients, indicating that the binding is specific. In an effort to map the ligand-binding domain of the SARS-CoV S glycoprotein, carboxy- and amino-terminal truncations of the S(1190) glycoprotein were constructed. Amino acids 270 to 510 were the minimal receptor-binding region of the SARS-CoV S glycoprotein as determined by flow cytometry. We speculate that amino acids 1 to 510 of the SARS-CoV S glycoprotein represent a unique domain containing the receptor-binding site (amino acids 270 to 510), analogous to the S1 subunit of other coronavirus S glycoproteins.</p>
dc.identifier.submissionpathoapubs/1527
dc.contributor.departmentMassachusetts Biologic Laboratories
dc.source.pages4552-60


Files in this item

Thumbnail
Name:
15078936.pdf
Size:
686.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record